4D label-free proteomics technology measures relative protein change from unlabeled peptide ions after liquid chromatography, trapped ion mobility spectrometry (TIMS), and Parallel Accumulation-Serial Fragmentation (PASEF). The four recorded dimensions are chromatographic retention time, mass-to-charge ratio (m/z), ion mobility, and signal intensity. Ion mobility is an extra gas-phase separation coordinate. It is not a labeling chemistry, not a synonym for data-independent acquisition (DIA), and not a spatial map of proteins inside cells or tissues.

Samples remain independently injected. Comparability is reconstructed after acquisition by alignment and normalization under one LC-TIMS plan. The valid claim is relative change of the same protein inside that analytical block. Ordinary 4D intensities are not molar concentrations. Researchers planning unlabeled TIMS-PASEF discovery can review the MtoZ Biolabs 4D Label-free Quantitative Proteomics Analysis Service for project-specific feasibility and analysis planning.

Core Technology Elements

1. Label-Free Quantification

Label-free workflows compare protein abundance without isotopic or isobaric tags on the discovery path. Each digest is injected separately, which supports open enrollment when new samples may still arrive. The trade-off is that run-order, chromatography, and mobility calibration must stay controlled. Removing chemical labels reduces tagging steps; it does not remove the need for matched extraction and digestion.

2. TIMS-PASEF Acquisition

Peptides are separated by nanoLC, accumulated in a TIMS tunnel, and fragmented with PASEF duty cycles that use trapped ion packets more efficiently than a simple serial MS/MS scheme alone. Collision cross section (CCS) related mobility information becomes part of each feature used for matching and interference review.

3. What "4D" Means in This Context

In TIMS-PASEF proteomics, 4D names retention time, m/z, ion mobility, and intensity. It does not mean microscopy-style spatial proteomics, and it does not invent a fourth quantitative algorithm that cancels batch effects. Data-dependent PASEF (ddaPASEF) and data-independent PASEF (diaPASEF) are acquisition choices on that platform. Either route can be unlabeled. 4D does not equal DIA.

4. Throughput and Project Fit

Because labeling kits are not required, 4D label-free projects can move from matched digests to acquisition without plex assembly. Speed still depends on prep quality, chromatography stability, and processing capacity. Skipping plant- or plasma-appropriate cleanup to save time usually increases missingness later.

Figure 1. 4D label-free technology records retention time, m/z, ion mobility, and intensity; ion mobility is the fourth MS dimension, not a tissue-space map.

End-to-end workflow control points are detailed in Comprehensive Guide to 4D Label-Free Quantitative Proteomics Workflow.

4D label-free proteomics is unlabeled relative discovery with TIMS-PASEF as extra separation and sampling.

Research Applications

1. Disease Mechanism Research

Disease-versus-control or genotype-versus-control contrasts can use 4D label-free matrices to nominate differentially abundant proteins under matched prep. Mechanism language should stay proportional to the relative table and QC, not to pathway drawings alone.

2. Biomarker Candidate Discovery

Proteins associated with phenotype or stage can be ranked for later confirmation. Discovery ranks are candidates. Diagnostic cutoffs require separately validated assays beyond ordinary 4D LFQ reporting.

3. Drug Response and Target Hypotheses

Pre- and post-treatment proteomes can show intended pathway shifts or compensatory changes. Off-target hypotheses remain research interpretations until orthogonal assays are added.

4. Systems-Level Relative Mapping

Broader cellular or tissue contrasts can support systems biology questions when the contrast is frozen and the LC-TIMS plan is one analytical block. Personalized or precision medicine certificates are outside ordinary research 4D label-free deliverables.

Application need	4D label-free often fits	Reassess
Inventory	Open relative discovery	Closed peptide panel already named
Enrollment	Separate unlabeled injections	All arms must share one isobaric plex
Selectivity aid	Mobility helps resolve co-eluting peptides	No TIMS-PASEF instrument in the plan
Claim	Relative change inside one LC-TIMS block	Absolute amount without standards
Follow-up	Shortlist for later PRM	Pathway map treated as proof

Figure 2. 4D label-free applications support relative discovery contrasts; they do not by themselves create diagnostic certificates.

Acquisition and claim boundaries for the same technology family are also discussed in What Is Label-Free Quantification in Proteomics?.

Limits That Shape Interpretation

Mobility reduces some precursor overlap, but it does not erase missing values, ion suppression, or column aging across independent injections. A later column change or TIMS calibration drift can open a new analytical block that ordinary normalization should not silently merge. PTM site quantification and absolute amount reporting need dedicated enrichment or calibrated standards beyond global 4D protein tables.

Conclusion

4D label-free proteomics technology combines unlabeled relative quantification with TIMS-PASEF so that retention time, m/z, ion mobility, and intensity jointly support discovery matrices. Correct use depends on matched prep, one LC-TIMS plan, and a relative claim that stays inside that block. Applications in disease modeling, biomarker candidate discovery, drug-response studies, and systems-level mapping remain strongest when those technology limits are respected. Researchers planning 4D label-free projects can contact MtoZ Biolabs to review sample type, contrast design, and acquisition mode, and can also consult the MtoZ Biolabs 4D Label-free Quantitative Proteomics Analysis Service for project-specific feasibility and workflow planning.